Innohep (Tinzaparin Sodium)

Innohep, a low molecular weight heparin, is used in several thromboembolic conditions.

• Deep vein thrombosis (DVT) prophylaxis: prevents clot formation in surgical patients at risk of DVT.
• Acute deep vein thrombosis treatment: facilitates clot resolution and reduces propagation in patients with confirmed DVT.
• Pulmonary embolism prevention and treatment: lowers the risk of embolic events in patients with or after a pulmonary embolism.
• Thromboembolic event prophylaxis: reduces clot risk in medically ill patients prone to venous thromboembolism.

• Tinzaparin sodium binds to antithrombin III, enhancing its inhibitory activity against activated factor X (FXa) and, to a lesser extent, thrombin (factor IIa). This accelerated inhibition disrupts the conversion of prothrombin to thrombin and the subsequent formation of fibrin, thereby impeding clot development while preserving a more predictable anticoagulant response compared with unfractionated heparin.

Innohep may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site pain or erythema
• Bruising at the injection site
• Mild bleeding (e.g., nosebleeds, gum bleeding)
• Nausea

Serious or Rare Side Effects

• Severe or uncontrolled bleeding
• Heparin‑induced thrombocytopenia
• Allergic reactions including anaphylaxis
• Skin necrosis at the injection site

When using Innohep, several precautions should be observed to minimize risk.

• Renal impairment: assess renal function and adjust dose or monitor closely.
• History of heparin‑induced thrombocytopenia: avoid use due to risk of recurrence.
• Concurrent anticoagulants or antiplatelet therapy: increased bleeding risk, consider temporary discontinuation.
• Surgery or invasive procedures: discontinue Innohep prior to the procedure as advised by the clinician.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Innohep can interact with other medicines, affecting its anticoagulant effect.

Major Interactions (Avoid)

• Other parenteral anticoagulants (e.g., unfractionated heparin, direct thrombin inhibitors): additive anticoagulation may cause severe bleeding.
• Thrombolytic agents (e.g., alteplase, streptokinase): combined use markedly increases hemorrhagic risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin: may enhance bleeding tendency.
• Antiplatelet agents (e.g., clopidogrel, ticagrelor): additive effect on platelet inhibition.
• Certain antibiotics (e.g., quinolones) that may affect platelet function: monitor for bleeding signs.